CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Keryx Biopharmaceuticals is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Keryx Biopharmaceuticals
1 Marina Park Drive
Phone: (617) 466-3500p:617 466-3500 Boston, MA  02210-1832  United States Fax: (617) 466-3501f:617 466-3501
This company was Merged or Acquired on 12/12/2018.
This company ceased filing statements with the SEC on 12/26/2018.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. Auryxia is marketed in Japan under the brand name Riona. It is investigating the use of ferric citrate for the treatment of iron deficiency anemia (IDA) in adults with non-dialysis dependent (NDD), CKD and NDD-CKD. It focuses on Keryx Patient Plus program to assist with patient accessibility to Auryxia. It has completed a Phase II clinical trial and a Phase III clinical trial of ferric citrate to gain Food and Drug Administration approval to use ferric citrate in patients with NDD-CKD.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/201812/31/2017YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Michael W.Rogers 58 9/11/2017 3/31/2016
Interim Chief Executive Officer, Director Jodie P.Morrison 43 4/27/2018 6/21/2016
Chief Financial Officer, Treasurer Scott A.Holmes 44 7/27/2015 7/27/2015
7 additional Officers and Directors records available in full report.

Business Names
Business Name
ACCESS Oncology, Inc.
Accumin Diagnostics, Inc.
AOI Pharma, Inc.
7 additional Business Names available in full report.

General Information
Number of Employees: 210 (As of 2/9/2018)
Outstanding Shares: 120,384,764 (As of 9/30/2018)
Shareholders: 45
Stock Exchange: NASD
Federal Tax Id: 134087132
Fax Number: (617) 466-3501
Email Address: bcohen@keryxus.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023